Search results
Showing 91 to 105 of 546 results for iv
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.
People with a rare condition that steadily worsens often leaving them dependent on a wheelchair and with shortened life expectancy, can now benefit from the first treatment to slow its progression.
SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)
NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .
Evidence-based recommendations on percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. This involves inserting a tube called a stent into or across the cystic duct. The aim is to allow bile to flow through the tube, bypassing the blockage and preventing further obstruction.
View recommendations for IPG720Show all sections
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
This quality standard covers the management of colorectal (bowel) cancer in adults. It includes managing local disease and secondary tumours (metastatic disease). It describes high-quality care in priority areas for improvement.
View quality statements for QS20Show all sections
Sections for QS20
- Quality statements
- Quality statement 1: Testing for Lynch syndrome
- Quality statement 2: Discussion about treatment options for early rectal cancer
- Quality statement 3: Testing to guide systemic anti-cancer treatment
- Quality statement 4: Follow-up for detecting local recurrence and distant metastases
- Update information
- About this quality standard
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
View recommendations for MTG65Show all sections
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
intra‑aortic balloon counter‑pulsation pump (IABP) better than the use of intravenous inotropes? Any explanatory notes(if applicable)...
treatment of people with acute heart failure is an inadequate response to intravenous diuretic therapy. This frequently leads to a...